Diagnostic Value of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Patients with Severe COVID-19 — 7 PLADs, China, January 21–February 10, 2020

WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? Coronavirus disease 2019 (COVID-19) causes symptoms ranging from mild to severe. Indicators for identifying severe COVID-19 infection have not been well identified, especially for young patients. WHAT IS ADDED BY THIS REPORT? Both neutrophil-lymphocyte ratio (...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Yan, Zhu, Dongshan, Shi, Nannan, Zhang, Lei, Chen, Guangkun, Ge, Youwen, Zhang, Zelei, Chen, Renbo, Liu, Sihong, Fan, Yipin, Zhang, Huamin, Wang, Yanping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2022
Materias:
Preplanned Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930406/
https://www.ncbi.nlm.nih.gov/pubmed/35356643
http://dx.doi.org/10.46234/ccdcw2022.047
_version_ 1784671059249725440
author Ma, Yan
Zhu, Dongshan
Shi, Nannan
Zhang, Lei
Chen, Guangkun
Ge, Youwen
Zhang, Zelei
Chen, Renbo
Liu, Sihong
Fan, Yipin
Zhang, Huamin
Wang, Yanping
author_facet Ma, Yan
Zhu, Dongshan
Shi, Nannan
Zhang, Lei
Chen, Guangkun
Ge, Youwen
Zhang, Zelei
Chen, Renbo
Liu, Sihong
Fan, Yipin
Zhang, Huamin
Wang, Yanping
author_sort Ma, Yan
collection PubMed
description WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? Coronavirus disease 2019 (COVID-19) causes symptoms ranging from mild to severe. Indicators for identifying severe COVID-19 infection have not been well identified, especially for young patients. WHAT IS ADDED BY THIS REPORT? Both neutrophil-lymphocyte ratio (NLR) [area under curve (AUC): 0.80; the odds ratios (OR) and 95% confidence intervals (95% CI): 1.30 (1.13–1.50)] and platelet-lymphocyte ratio (PLR) [AUC: 0.87; OR (95% CI): 1.05 (1.01–1.09)] were determined to be indicators for recognition of patients with severe COVID-19 in young patients less than age 40. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? NLR and PLR are useful indicators for identifying patients with severe COVID-19, especially in young patients less than age 40.
format Online
Article
Text
id pubmed-8930406
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention
record_format MEDLINE/PubMed
spelling pubmed-89304062022-03-29 Diagnostic Value of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Patients with Severe COVID-19 — 7 PLADs, China, January 21–February 10, 2020 Ma, Yan Zhu, Dongshan Shi, Nannan Zhang, Lei Chen, Guangkun Ge, Youwen Zhang, Zelei Chen, Renbo Liu, Sihong Fan, Yipin Zhang, Huamin Wang, Yanping China CDC Wkly Preplanned Studies WHAT IS ALREADY KNOWN ABOUT THIS TOPIC? Coronavirus disease 2019 (COVID-19) causes symptoms ranging from mild to severe. Indicators for identifying severe COVID-19 infection have not been well identified, especially for young patients. WHAT IS ADDED BY THIS REPORT? Both neutrophil-lymphocyte ratio (NLR) [area under curve (AUC): 0.80; the odds ratios (OR) and 95% confidence intervals (95% CI): 1.30 (1.13–1.50)] and platelet-lymphocyte ratio (PLR) [AUC: 0.87; OR (95% CI): 1.05 (1.01–1.09)] were determined to be indicators for recognition of patients with severe COVID-19 in young patients less than age 40. WHAT ARE THE IMPLICATIONS FOR PUBLIC HEALTH PRACTICE? NLR and PLR are useful indicators for identifying patients with severe COVID-19, especially in young patients less than age 40. Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2022-03-11 /pmc/articles/PMC8930406/ /pubmed/35356643 http://dx.doi.org/10.46234/ccdcw2022.047 Text en Copyright and License information: Editorial Office of CCDCW, Chinese Center for Disease Control and Prevention 2022 https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution-NonCommercial-Share Alike 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ (https://creativecommons.org/licenses/by-nc-sa/4.0/)
spellingShingle Preplanned Studies
Ma, Yan
Zhu, Dongshan
Shi, Nannan
Zhang, Lei
Chen, Guangkun
Ge, Youwen
Zhang, Zelei
Chen, Renbo
Liu, Sihong
Fan, Yipin
Zhang, Huamin
Wang, Yanping
Diagnostic Value of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Patients with Severe COVID-19 — 7 PLADs, China, January 21–February 10, 2020
title Diagnostic Value of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Patients with Severe COVID-19 — 7 PLADs, China, January 21–February 10, 2020
title_full Diagnostic Value of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Patients with Severe COVID-19 — 7 PLADs, China, January 21–February 10, 2020
title_fullStr Diagnostic Value of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Patients with Severe COVID-19 — 7 PLADs, China, January 21–February 10, 2020
title_full_unstemmed Diagnostic Value of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Patients with Severe COVID-19 — 7 PLADs, China, January 21–February 10, 2020
title_short Diagnostic Value of Neutrophil-Lymphocyte Ratio and Platelet-Lymphocyte Ratio in Patients with Severe COVID-19 — 7 PLADs, China, January 21–February 10, 2020
title_sort diagnostic value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with severe covid-19 — 7 plads, china, january 21–february 10, 2020
topic Preplanned Studies
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8930406/
https://www.ncbi.nlm.nih.gov/pubmed/35356643
http://dx.doi.org/10.46234/ccdcw2022.047
work_keys_str_mv AT mayan diagnosticvalueofneutrophillymphocyteratioandplateletlymphocyteratioinpatientswithseverecovid197pladschinajanuary21february102020
AT zhudongshan diagnosticvalueofneutrophillymphocyteratioandplateletlymphocyteratioinpatientswithseverecovid197pladschinajanuary21february102020
AT shinannan diagnosticvalueofneutrophillymphocyteratioandplateletlymphocyteratioinpatientswithseverecovid197pladschinajanuary21february102020
AT zhanglei diagnosticvalueofneutrophillymphocyteratioandplateletlymphocyteratioinpatientswithseverecovid197pladschinajanuary21february102020
AT chenguangkun diagnosticvalueofneutrophillymphocyteratioandplateletlymphocyteratioinpatientswithseverecovid197pladschinajanuary21february102020
AT geyouwen diagnosticvalueofneutrophillymphocyteratioandplateletlymphocyteratioinpatientswithseverecovid197pladschinajanuary21february102020
AT zhangzelei diagnosticvalueofneutrophillymphocyteratioandplateletlymphocyteratioinpatientswithseverecovid197pladschinajanuary21february102020
AT chenrenbo diagnosticvalueofneutrophillymphocyteratioandplateletlymphocyteratioinpatientswithseverecovid197pladschinajanuary21february102020
AT liusihong diagnosticvalueofneutrophillymphocyteratioandplateletlymphocyteratioinpatientswithseverecovid197pladschinajanuary21february102020
AT fanyipin diagnosticvalueofneutrophillymphocyteratioandplateletlymphocyteratioinpatientswithseverecovid197pladschinajanuary21february102020
AT zhanghuamin diagnosticvalueofneutrophillymphocyteratioandplateletlymphocyteratioinpatientswithseverecovid197pladschinajanuary21february102020
AT wangyanping diagnosticvalueofneutrophillymphocyteratioandplateletlymphocyteratioinpatientswithseverecovid197pladschinajanuary21february102020

Ejemplares similares